Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Salicylamides" patented technology

Amides of salicylic acid.

Isoquinolone derivative as well as preparation method and application thereof

The invention relates to an isoquinolone derivative as well as a preparation method and application thereof. According to a synthesis method, the isoquinolone derivative is prepared from various substituted acetamides as the raw material and a nonmetal as a catalyst under the action of an initiator. Compared with an existing synthesis method, the synthesis method provided by the invention is more economical and environment-friendly, and use of a metal catalyst is avoided. In addition, the synthesis method also has the advantages of being simple in operation, wide in atom economy and wide in substrate adaptability. Furthermore, the compound has a good application prospect in the aspects, such as tumors, cardiovascular diseases, inflammatory diseases, metabolic diseases and neurodegenerative diseases.
Owner:CHINA PHARM UNIV

Salicylamide antitumor compound and its synthesis method and application

The invention discloses a class of compounds with antitumor activity. The structural formula is as follows: In the formula, R is one or two substituents of ethynyl, chlorine, fluorine, trifluoromethyl and 3-fluorobenzyloxy; X is O or NH; Y is CH2 or CO (carbonyl); Z is H or methoxy; n=5 or 6. The salicylic amide compounds in the structural formula are synthesized from 5-nitrosalicylic acid or 4-methoxysalicylic acid and aniline derivatives through amidation, reduction, and reaction with monoethyl pimelic acid chloride. . The compound has a novel structure and the synthesis method is easy to realize. The anti-tumor activity test showed that it has inhibitory effect on the growth of human liver cancer cells (HepG-2), human colon cancer (SW 480) and human prostate cancer cells (PC3), and the activity of most compounds is stronger than that of gefitinib. The use of preparing anti-tumor drug preparations.
Owner:XI AN JIAOTONG UNIV

Composite oxide catalyst for compounding salicylamide by urea and phenol, preparation method and application of composite oxide catalyst

The invention discloses a composite oxide catalyst for compounding salicylamide by urea and phenol, a preparation method and application of the composite oxide catalyst. The preparation method comprises the steps of taking nitrate of various metal as a starting material, taking sodium hydroxide and sodium carbonate as a precipitant, preparing a hydrotalcite-like precursor by adopting a method that coprecipitation is performed first, and then hydro-thermal treatment is performed, performing high-temperature calcination, and obtaining the composite oxide catalyst represented in the following general formula: MgxAlyMzOm, wherein M is one of alkaline-earth metal, transition metal or rare-earth metal. Compared with the prior art, the composite oxide catalyst has the advantages of simple preparation method, large specific surface, high activity and the like. Under the effect of the catalyst, the conversion rate of urea can reach 100 percent, the yield of the salicylamide is greater than 99 percent. Meanwhile, the composite oxide catalyst is easy to separate and recycle, and good in catalytic stability, is free from pollution of environment and production equipment, and can still keep higher catalytic activity without regeneration.
Owner:ZAOZHUANG UNIV

Oral Care Compositions

An oral care composition comprising zinc phosphate, stannous fluoride and a salicylamide, as well as methods of using the same.
Owner:COLGATE PALMOLIVE CO

A composite oxide catalyst for synthesizing salicylamide from urea and phenol, its preparation method and application

The invention discloses a composite oxide catalyst for compounding salicylamide by urea and phenol, a preparation method and application of the composite oxide catalyst. The preparation method comprises the steps of taking nitrate of various metal as a starting material, taking sodium hydroxide and sodium carbonate as a precipitant, preparing a hydrotalcite-like precursor by adopting a method that coprecipitation is performed first, and then hydro-thermal treatment is performed, performing high-temperature calcination, and obtaining the composite oxide catalyst represented in the following general formula: MgxAlyMzOm, wherein M is one of alkaline-earth metal, transition metal or rare-earth metal. Compared with the prior art, the composite oxide catalyst has the advantages of simple preparation method, large specific surface, high activity and the like. Under the effect of the catalyst, the conversion rate of urea can reach 100 percent, the yield of the salicylamide is greater than 99 percent. Meanwhile, the composite oxide catalyst is easy to separate and recycle, and good in catalytic stability, is free from pollution of environment and production equipment, and can still keep higher catalytic activity without regeneration.
Owner:ZAOZHUANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products